NATCO PHARMA LTD. - 524816 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Postal Ballot notice dated 14th February 2022 for appointment/re-appointment of Directors22-02-2022
22-02-2022
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation for the quarter and nine months ended 31st December 202117-02-2022
Earnings Call for Q3FY22 of Natco Pharma
Conference Call with Natco Pharma Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript.15-02-2022
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Newspaper Publication
News Paper Publication copies for the quarter and nine months ended 31st December, 2021 and Notice of 3rd Interim Dividend Record Date15-02-2022
Natco Pharma consolidated net profit up 27% to Rs 80 crore in Dec quarter
The Hyderabad-based company had reported a net profit of Rs 63.4 crore in the October-December period of previous fiscal14-02-2022
NATCO PHARMA LTD. - 524816 - Board declares Third Interim Dividend
Natco Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 14, 2022, inter alia, has declared 3rd interim dividend of Rs. 2/- each per Equity share of Rs. 2/- each for the financial year 2021-22 (which is 100% on the nominal value of the equity share). The payment of said interim dividend will start from March 04, 2022.14-02-2022
NATCO PHARMA LTD. - 524816 - Record Date Fixed For Interim Dividend
Record Date Fixed for Interim Dividend14-02-2022
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Earnings Call with Investors / Analysts at 11.00 a.m. IST on Tuesday, February 15, 2022,09-02-2022
NATCO PHARMA LTD. - 524816 - Closure of Trading Window
TRADING WINDOW for dealing in the securities of the Company by the Employee(s), connected persons and their immediate relatives will be closed from 5th February, 2022 to 16th February, 2022 (both days inclusive). Trading window will be re-opened on 17th February 2022.05-02-2022
NATCO PHARMA LTD. - 524816 - Board to consider Q3 results & Third Interim Dividend on Feb 14, 2022
Natco Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled to be held on February 14, 2022, inter alia, to consider the following items of business and related matters:1. To consider the Unaudited Financial Results for the quarter and nine months ended December 31, 2021 (Q3).2. To consider third interim dividend, if any, for the financial year 2021-22.Further, pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time TRADING WINDOW for dealing in the securities of the Company by the Employee(s), connected persons and their immediate relatives will be closed from February 05, 2022 to February 16, 2022 (both days inclusive). Trading window will be re-opened on February 17, 2022.05-02-2022